Halozyme - Making The Most Of ENHANZE Opportunities : vimars

Shares of Halozyme Therapeutics Inc. (HALO) are down 37% from their 52-week high of $59.46, recorded last December, and trade around $37..

Related Keywords

Bristol Myers Squibb , Roche Phesgo , Eli Lilly , Pfizer , Halozyme Therapeutics Inc , Halozyme Therapeutics , Horizon Therapeutics , Viiv Healthcare , Generalized Myasthenia , Fda , Gnoche , Halo , Enhanze , Opdivo ,